The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib, multicenter, single-blinded, placebo-controlled, sequential dose-escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer (LAHNC) receiving induction chemotherapy (ICT).
Sewanti Atul Limaye
Research Funding - ActoGeniX
Stephen T. Sonis
Employment or Leadership Position - Biomodels; Biomodels
Consultant or Advisory Role - ActoGeniX; Clinical Assistance Program; Galera Therapeutics; Inimex; Novartis; Pfizer; Polymedix; Progenics; SciClone
Fiona Cilli
Employment or Leadership Position - ActoGeniX
A. Dimitrios Colevas
Research Funding - ActoGeniX
Michael Brennan
Consultant or Advisory Role - CAP
Research Funding - ActoGeniX
Kenneth Hu
Research Funding - ActoGeniX
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Sanofi
Barbara A. Murphy
Research Funding - ActoGeniX